# Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures

> **NCT01913405** · PHASE3 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 30 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** PEGylated Recombinant factor VIII (rFVIII)

## Key facts

- **NCT ID:** NCT01913405
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-20
- **Primary completion:** 2016-09-23
- **Final completion:** 2016-09-23
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01913405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01913405, "Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01913405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*